COVID-19 Clinical Trial
Official title:
Open Label, Multi-Center Phase 3 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2
Verified date | February 2024 |
Source | Health Institutes of Turkey |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The inactivated Booster Phase 3 study aims to determine the efficacy, safety, and immunogenicity of inactivated COVID-19 vaccines in subjects with a minimum of 90 days and a maximum of 270 days after the second dose of CoronaVac vaccine.
Status | Completed |
Enrollment | 4340 |
Est. completion date | February 5, 2024 |
Est. primary completion date | May 10, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 59 Years |
Eligibility | Subjects must meet all of the following inclusion criteria to be eligible for inclusion in the study: Inclusion Criteria: 1. Subjects willing and able to give signed informed consent to participate in study, 2. Healthy male or female aged 18 - 59 years (including both groups), 3. Subjects who were vaccinated with CoronaVac for 2 doses and who had a minimum of 90 days and a maximum of 270 days after the second dose, 4. Subjects with minimum 28 days and maximum 42 days between CoronaVac 1st and 2nd dose vaccines, 5. Female subjects of childbearing potential should be willing to ensure that they or their partner use effective birth control methods continuously from 1 month before and up to 3 months after vaccination, Male subjects of potential to have children should be willing to ensure that they or their partner use effective birth control methods continuously from 1 month before and up to 3 months after vaccination, 6. In the opinion of the investigator, subjects capable and willing to comply with all study requirements, 7. Subjects are willing to agree to abstain from donating blood during the study. Subjects meeting any of the following criteria will not be included in the study: Exclusion Criteria: 1. Administration of any vaccine (registered or investigational) other than study intervention within 30 days before and after each study vaccine (one week for authorized seasonal flu vaccine or pneumococcal vaccine), 2. Pre-or planned use of another vaccine or product likely to affect the study (e.g. adenovirus vectored vaccines, any coronavirus vaccine), 3. Known history of SARS-CoV-2 infection, 4. Pregnant and puerperant subjects (subjects who become pregnant 2 months after vaccination will continue to study), 5. Subjects with fever (above 37,8°C) at the time of vaccination and/or up to 72 hours before (After the acute condition has resolved, the subject can be screened again), 6. Administration of immunoglobulins and/or any blood product within 3 months prior to vaccination, 7. Any confirmed or suspected immunosuppressive or immunodeficiency state; asplenia; recurrent severe infections and use of immunosuppressants (less than =14 days) in the last 6 months, excluding topical steroids or short-term oral steroids, 8. Possible history of allergic disease or reaction (e.g. to the active substance) by any component of the study vaccines, 9. Any history of anaphylaxis, 10. Current cancer diagnosis or treatment (excluding basal cell carcinoma of the skin and cervical carcinoma in situ), 11. History of bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venipuncture, 12. Continued use of anticoagulants such as coumarins and related anticoagulants (i.e. warfarin) or new oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and edoxaban), 13. Cerebral venous sinus thrombosis, antiphospholipid syndrome, or a history of heparin-induced thrombocytopenia and thrombosis (HITT or HIT type 2), 14. Suspected or known current alcohol or drug addiction, 15. Any other significant disease, disorder or finding that could significantly increase the subject's risk for participation in the study, affect the subject's ability to participate in the study, or impair the interpretation of study data; severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, kidney disease, endocrine disorder, and neurological disease (mild/moderate well-controlled comorbidities are permitted), 16. History of active or previous autoimmune neurological disorders (e.g. multiple sclerosis, Guillain-Barre syndrome, transverse myelitis) (Bell's palsy will not be an exclusion criterion), 17. Subjects with severe renal impairment or liver failure, 18. Subjects who will undergo scheduled elective surgery during the study, 19. Subjects with a life expectancy of less than 6 months, 20. Subject who participated in another clinical trial study involving an investigational product in the past 12 weeks, 21. In case of clinical necessity, a COVID-19 PCR (polymerase chain reaction) test will be requested from the subjects, and subjects who are positive will be excluded from the study, 22. Acute respiratory disease (moderate or severe illness with or without fever). (Subjects may be screened again after acute condition has resolved), 23. Insufficient level of Turkish to perform the informed consent, except where briefing by an independent witness can be provided and is available. |
Country | Name | City | State |
---|---|---|---|
Turkey | Çukurova University Faculty of Medicine, Department of Infectious Diseases | Adana | |
Turkey | Diskapi SUAM Infectious Diseases and Clinical Microbiology | Ankara | |
Turkey | T.R. Ministry of Health Ankara City Hospital, Infectious Diseases and Clinical Microbiology Clinic | Ankara | |
Turkey | T.R. Ministry of Health Ankara Keçiören Sanatorium Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital | Ankara | Turkey Region |
Turkey | T.R. Ministry of Health Antalya Training And Research Hospital | Antalya | |
Turkey | T.R. Ministry of Health Aydin State Hospital | Aydin | |
Turkey | T.R. Ministry of Health Balikesir Atatürk City Hospital | Balikesir | |
Turkey | T.R. Ministry of Health Abant Izzet Baysal University Training and Research Hospital | Bolu | |
Turkey | T.R. Ministry of Health Bursa City Hospital | Bursa | |
Turkey | Uludag University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology | Bursa | |
Turkey | T.R. Ministry of Health Denizli Acipayam State Hospital | Denizli | |
Turkey | T.R. Ministry of Health Elazig Fethi Sekin City Hospital | Elazig | |
Turkey | Erzincan Binali Yildirim University Training and Research Hospital Traditional and Complementary Medicine Application Center - GETAT | Erzincan | |
Turkey | T.R. Ministry of Health Erzurum Regional Training and Research Hospital | Erzurum | |
Turkey | Eskisehir Osmangazi University Eskisehir Osmangazi University Health, Application and Research Hospital | Eskisehir | |
Turkey | T.R. Ministry of Health Eskisehir City Hospital | Eskisehir | |
Turkey | T.R. Ministry of Health Dr. Ersin Arslan Training and Research Hospital | Gaziantep | |
Turkey | Cerrahpasa Faculty of Medicine, Department of Internal Medicine - Department of Infectious Diseases and Clinical Microbiology | Istanbul | |
Turkey | T.R. Ministry of Health Basaksehir Çam ve Sakura City Hospital | Istanbul | |
Turkey | T.R. Ministry of Health Istanbul Provincial Health Directorate Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital (Prof. Dr. Feriha Öz Emergency Hospital) | Istanbul | |
Turkey | T.R. Ministry of Health Istanbul Sisli Hamidiye Etfal Training and Research Hospital, Clinical Microbiology Clinic | Istanbul | |
Turkey | T.R. Ministry of Health Kartal Dr. Lütfi Kirdar City Hospital Infectious Diseases | Istanbul | |
Turkey | University of Health Sciences Istanbul Ümraniye Training and Research Hospital | Istanbul | |
Turkey | T.R. Ministry of Health Izmir Katip Çelebi University Atatürk Training and Research Hospital, Infectious Diseases Clinic | Izmir | |
Turkey | T.R. Ministry of Health Izmir Provincial Health Directorate Health Sciences University Dr Suat Seren Chest Diseases And Chest Surgery Training And Research Hospital | Izmir | |
Turkey | T.R. Ministry of Health Izmir Provincial Health Directorate Izmir Health Sciences University Tepecik Training and Research Hospital, Infectious Diseases | Izmir | |
Turkey | Kahramanmaras Sütçü Imam University Infections Diseases | Kahramanmaras | |
Turkey | Erciyes University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology | Kayseri | |
Turkey | T.R. Ministry of Health Kayseri City Training and Research Hospital, Infectious Diseases and Clinical Microbiology Department | Kayseri | |
Turkey | Kirikkale University Faculty of Medicine, Department of Internal Medicine | Kirikkale | |
Turkey | Kocaeli University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology | Kocaeli | |
Turkey | T.R. Ministry of Health Kocaeli Health Sciences University Derince Training And Research Hospital | Kocaeli | |
Turkey | T.R. Ministry of Health Konya City Hospital | Konya | |
Turkey | Kütahya University of Health Sciences, Infectious Diseases and Clinic | Kütahya | |
Turkey | Malatya Inönü University Faculty of Medicine, Department of Infectious Diseases | Malatya | |
Turkey | T.R. Ministry of Health Manisa City Hospital | Manisa | |
Turkey | T.R. Ministry of Health Mersin City Training and Research Hospital | Mersin | |
Turkey | Sanliurfa Harran University Hospital | Sanliurfa | |
Turkey | T.R. Ministry of Health Tekirdag Çorlu District State Hospital | Tekirdag | |
Turkey | Health Sciences University Kanuni Training and Research Hospital Infectious Diseases and Clinical Microbiology | Trabzon | |
Turkey | Van Yüzüncü Yil University Hospital, Faculty of Medicine, Infectious Diseases and Clinical Microbiology | Van |
Lead Sponsor | Collaborator |
---|---|
Health Institutes of Turkey |
Turkey,
Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, Nakao C, Rayaprolu V, Rawlings SA, Peters B, Krammer F, Simon V, Saphire EO, Smith DM, Weiskopf D, Sette A, Crotty S. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb 5;371(6529):eabf4063. doi: 10.1126/science.abf4063. Epub 2021 Jan 6. — View Citation
Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, Ledgerwood JE, Mascola JR, Graham BS, Lin BC, O'Dell S, Schmidt SD, Widge AT, Edara VV, Anderson EJ, Lai L, Floyd K, Rouphael NG, Zarnitsyna V, Roberts PC, Makhene M, Buchanan W, Luke CJ, Beigel JH, Jackson LA, Neuzil KM, Bennett H, Leav B, Albert J, Kunwar P; mRNA-1273 Study Group. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021 Jun 10;384(23):2259-2261. doi: 10.1056/NEJMc2103916. Epub 2021 Apr 6. No abstract available. Erratum In: N Engl J Med. 2022 Feb 3;386(5):500. — View Citation
Kumar A, Singh R, Kaur J, Pandey S, Sharma V, Thakur L, Sati S, Mani S, Asthana S, Sharma TK, Chaudhuri S, Bhattacharyya S, Kumar N. Wuhan to World: The COVID-19 Pandemic. Front Cell Infect Microbiol. 2021 Mar 30;11:596201. doi: 10.3389/fcimb.2021.596201. eCollection 2021. — View Citation
Madhi SA, Izu A, Pollard AJ. ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply. N Engl J Med. 2021 Aug 5;385(6):571-572. doi: 10.1056/NEJMc2110093. Epub 2021 Jul 21. No abstract available. — View Citation
Pavel STI, Yetiskin H, Aydin G, Holyavkin C, Uygut MA, Dursun ZB, Celik I, Cevik C, Ozdarendeli A. Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey. PLoS One. 2020 Sep 16;15(9):e0238614. doi: 10.1371/journal.pone.0238614. eCollection 2020. — View Citation
Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, Colpitts T, Bennett H, Boyoglu-Barnum S, Shi W, Moliva JI, Sullivan NJ, Graham BS, Carfi A, Corbett KS, Seder RA, Edwards DK. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. N Engl J Med. 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179. Epub 2021 Mar 17. No abstract available. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Protection rates of Turkovac and CoronaVac vaccines against symptomatic COVID-19 | Protection rates of Turkovac and CoronaVac vaccines against symptomatic COVID-19 confirmed by RT-PCR at least 14 days after booster vaccination dose. | At least 14 days after booster vaccination dose | |
Primary | To Evaluate the SARS-CoV2 anti-spike protein immunoglobulin G | The change in the amount of SARS-CoV2 anti-spike protein immunoglobulin G in the 28th day compared to the baseline is 2 times or more | 28 days after booster vaccination dose | |
Primary | Evaluation of SARS-CoV2 Neutralizing Antibodies | The change in the amount of SARS-CoV2 neutralizing antibodies in the 28th day compared to the baseline is 2 times or more | 28 days after booster vaccination dose | |
Primary | T-Cell Evaluation | IL-2, TNF-alpha and IFN-gamma levels in T cells changed by 2 times or more on day 28 compared to baseline for 35 - 40 subjects | 28 days after booster vaccination dose | |
Secondary | Incidence of Adverse Events (AE) | To evaluate the safety of booster dose vaccines by determining the incidence of adverse reactions. | On days 7 and 14 days after vaccination | |
Secondary | Incidence of Serious Adverse Events (SAE) | To evaluate the safety of booster dose vaccines by determining the incidence of serious adverse reactions. | 168 days after vaccination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|